Peptide marketing runs on citations the way COAs run on purity percentages: the number is real, the implication usually isn't. This guide walks the genuinely important research — the studies everyone in this space cites, whether they've read them or not — and tells you what each one actually demonstrated, in what system. Every study below is indexed in our research library with its experimental model stated, and every one resolves on PubMed if you want to check us. We encourage it.
The gold standard: GLP-1 clinical trials
If "best research" means the strongest evidence type, nothing else in the peptide world is close: semaglutide and tirzepatide went through the full arc of large randomized controlled human trials that ended in FDA approvals for the pharmaceutical products. That literature is why the GLP-1 class dominates medicine right now — and it's the benchmark every other compound on this page should be measured against. Retatrutide's late-stage trial program is the next chapter being written. Note what this evidence attaches to: the approved, manufactured drug — not any particular gray-market vial sharing the molecule's name.
The landmark preclinical work, compound by compound
BPC-157. The two studies vendors cite most are rat orthopedic models: a 2011 Achilles-tendon study showing accelerated tendon-fibroblast outgrowth, and a 2010 medial-collateral-ligament study following healing for 90 days. Both are real, careful animal studies. A 2025 systematic review of 36 studies spanning 1993–2024 is now the best single entry point — and its most important finding is the one marketers skip: the evidence base is almost entirely preclinical. Full citations: BPC-157 research record.
TB-500 / thymosin beta-4. The foundational paper is a 1999 rat full-thickness wound study showing accelerated healing, followed by 2004 work on angiogenesis and hair-follicle development in normal and aged rodents. Two decades of vascular-biology reviews followed. Model to remember: rodents and cell migration assays. Citations: TB-500 research record.
GHK-Cu. The origin study is from 1988 — collagen synthesis stimulation in fibroblast cultures — and the modern record includes gene-expression reviews and a 2023 study pairing GHK-Cu with hyaluronic acid in human dermal fibroblasts and ex-vivo skin. This is the rare research peptide whose best evidence is in its actual use context (topical/cosmetic). Citations: GHK-Cu research record.
KPV. A tripeptide fragment of alpha-MSH with a tidy story: 2003 work dissecting its anti-inflammatory core, 2008 studies showing PepT1-mediated uptake reducing intestinal inflammation in colitis models, and 2017 nanoparticle-delivery work in ulcerative-colitis mice. Every key study is a mouse or cell-line model. Citations: KPV research record.
How to read any peptide study in 90 seconds
Find the model first — it's in the abstract's methods sentence. Cells in a dish establish mechanism; animal models establish physiological plausibility; controlled human trials establish what actually happens in people. Then check three things: sample size, whether there was a control group, and who funded it. A rat study with n=12 and a clean design is worth more than it sounds; an uncontrolled "clinical experience" write-up is worth less. And any citation that won't resolve on PubMed isn't a citation — it's set dressing.
Why we publish the model on every citation
Our research library lists the experimental system next to every study — "rat medial collateral ligament transection," "human dermal fibroblasts," "systematic review of 36 studies" — because that single field is the difference between a citation list and a claims page. No other directory in this space publishes it. It's also, not coincidentally, what keeps this site honest.
For research use only. This article is educational and makes no health, dosing, or usage claims of any kind.